IP Library Patent Application 13665588
Patent Application
App. No. 13/665,588

FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/665,588
Abstract

This invention provides a process for sequencing single-stranded DNA employing modified nucleotides.

Claims (37)

1 . A method for determining the sequence of a DNA comprising performing the following steps for each residue of the DNA to be sequenced:

(a) contacting the DNA with a DNA polymerase in the presence of (i) a primer and (ii) four nucleotide analogues under conditions permitting the DNA polymerase to catalyze DNA synthesis, wherein (1) the nucleotide analogues consist of an analogue of dGTP, an analogue of dCTP, an analogue of dTTP or dUTP, and an analogue of dATP, (2) each nucleotide analogue comprises (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine or uracil, and analogues thereof, (ii) a deoxyribose, (iii) a moiety cleavably linked to the 3′-oxygen of the deoxyribose and (iv) a unique label cleavably linked to the base, so that a nucleotide analogue complementary to the residue being sequenced is incorporated into the DNA by the DNA polymerase, and (3) each of the four analogues has a unique label which is different than the unique labels of the other three analogues;

(b) removing unbound nucleotide analogues;

(c) again contacting the DNA with a DNA polymerase in the presence of (i) a primer and (ii) four reversible terminators under conditions permitting the DNA polymerase to catalyze DNA synthesis, wherein (1) the reversible terminators consist of an analogue of dGTP, an analogue of dCTP, an analogue of dTTP or dUTP, and an analogue of dATP, (2) each nucleotide analogue comprises (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine or uracil, and analogues thereof, which base does not have a unique label bound thereto, (ii) a deoxyribose, and (iii) a moiety cleavably linked to the 3′-oxygen of the deoxyribose;

(d) removing unbound reversible terminators;

(e) determining the identity of the nucleotide analogue incorporated in step (a) via determining the identity of the corresponding unique label, with the proviso that step (e) can either precede step (c) or follow step (d); and

(f) following step (e), except with respect to the final DNA residue to be sequenced, cleaving from the incorporated nucleotide analogues the unique label, if applicable, and the moiety linked to the 3′-oxygen atom of the deoxyribose,

thereby determining the sequence of the DNA.

2 . The method of claim 1 , wherein step (e) is performed before step (c).

3 . The method of claim 1 , wherein the moiety cleavably linked to the 3′-oxygen of the deoxyribose is chemically cleavable or photocleavable.

4 . (canceled)

5 . (canceled)

6 . The method of claim 1 , wherein the unique label is bound to the base via a chemically cleavable or photocleavable linker.

7 . The method of claim 1 , wherein the unique label bound to the base via a cleavable linker is a dye, a fluorophore, a chromophore, a combinatorial fluorescence energy transfer tag, a mass tag, or an electrophore.

8 . (canceled)

9 . (canceled)

10 . The method of claim 1 , wherein the primer is a self-priming moiety.

11 . The method of claim 1 , wherein the DNA is bound to a solid substrate.

12 . The method of claim 11 , wherein the DNA is bound to the solid substrate via 1,3-dipolar azide-alkyne cycloaddition chemistry.

13 . (canceled)

14 . The method of claim 11 , wherein the DNA is alkyne-labeled.

15 . The method of claim 11 , wherein the DNA is bound to the solid substrate via a polyethylene glycol molecule and the solid substrate is azide-functionalized.

16 . The method of claim 11 , wherein the DNA is immobilized on the solid substrate via an azido linkage, an alkynyl linkage, or biotin-streptavidin interaction.

17 . The method of claim 11 , wherein the solid substrate is in the form of a chip, a bead, a well, a capillary tube, a slide, a wafer, a filter, a fiber, a porous media, or a column.

18 . The method of claim 11 , wherein the solid substrate is gold, quartz, silica, plastic, glass, diamond, silver, metal, or polypropylene.

19 . The method of claim 11 , wherein the solid substrate is porous.

20 - 27 . (canceled)

28 . A kit for performing the method of claim 1 , comprising, in separate compartments,

(a) nucleotide analogues of (i) GTP, (ii) ATP, (iii) CTP and (iv) TTP or UTP, wherein each analogue comprises (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine or uracil, or an analogue thereof, (ii) a deoxyribose, (iii) a cleavable moiety bound to the 3′-oxygen of the deoxyribose and (iv) a unique label bound to the base via a cleavable linker,

(b) reversible terminators comprising a nucleotide analogue of (i) GTP, (ii) ATP, (iii) CTP and (iv) TTP or UTP, wherein each analogue comprises (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine or uracil, or an analogue thereof, which base does not have a unique label bound thereto, (ii) a deoxyribose, and (iii) a cleavable moiety bound to the 3′-oxygen of the deoxyribose;

(c) reagents suitable for use in DNA polymerization; and

(d) instructions for use.

29 . The kit of claim 28 , wherein the nucleotide analogues of part (a) are 3′-O-allyl-dGTP-allyl-Cy5, 3′-O-allyl-dCTP-allyl-Bodipy-FL-510, 3′-O-allyl-dATP-allyl-ROX and 3′-O-allyl-dUTP-allyl-R6G.

30 . The kit of claim 28 , wherein the nucleotide analogues of part (a) are 3′-O-allyl-dGTP-allyl-Bodipy-FL-510, 3′-O-allyl-dCTP-allyl-Bodipy-650, 3′-O-allyl-dATP-allyl-ROX and 3′-O-allyl-dUTP-allyl-R6G.

31 . The kit of claim 28 , wherein the nucleotide analogues of part (a) are 3′-O-allyl-dGTP-allyl-Bodipy-650, 3′-O-allyl-dCTP-allyl-Bodipy-FL-510, 3′-O-allyl-dATP-allyl-ROX and 3′-O-allyl-dUTP-allyl-R6G.

32 . The kit of claim 28 , wherein the nucleotide analogues of part (b) are 3′-O-allyl-dGTP, 3′-O-allyl-dCTP, 3′-O-allyl-dATP and 3′-O-allyl-dUTP.

33 . The method of claim 28 , wherein the reversible terminators in step (c) are 3′-O-2-nitrobenzyl-dGTP, 3′-O-2-nitrobenzyl-dCTP, 3′-O-2-nitrobenzyl-dATP and 3′-O-2-nitrobenzyl-dUTP.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 9, 2013
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029595/0582 →